$21.5M Series A financing round to advance pipeline of next-gen engineered off-the-shelf NK cell therapies
Funding round led by current investors Acorn Bioventures and ALSHC; joined by new investor Cormorant Asset Management
Financing will drive multiple pre-clinical programs through IND-enabling studies and the continued progression of a GMP manufacturing capability
The groundbreaking approvals of two CAR-T therapies in 2017 was the climax of more than sixty years of devoted research. In the 1950s, the discovery of bone marrow transplantation laid the foundation for developing CAR-T therapy, as it was the first time that living cells were infused into blood cancer patients for the control of cancer.
As early as 1900s, researchers were becoming aware that T cells could easily search, recognize and kill cancer cells. To do this, the cells need a “guide” to direct them to the tumors, and thus, antibodies emerged as a valuable scientific and medical tool. [Read more…]
CAR-T cell therapy is as a type of immunotherapy that teaches T cells to recognize and destroy cancer. This article provides a comprehensive list of CAR-T therapy companies worldwide. Read on to learn more about innovative CAR-T cell therapy companies and the technologies they are using to fight cancer.
In this article:
CAR-T is a promising type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the capacity to recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.”
Since the approval of the first CAR-T cell therapeutic in 2017, widespread research, proliferating clinical trials, aggressive M&A activity, and lucrative IPOs have created a robust CAR-T cell market. [Read more…]
Scientific progress within the field of cancer immunotherapy has led to five CAR-T cell therapy approvals: Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), and Abecma (idecabtagene vicleucel). Additionally, JW Therapeutics has announced NMPA approval of Relmacabtagene Autoleucel Injection in China. This is the first CAR-T product independently developed in China and approved as a Category 1 biologics product, as well as the sixth approved CAR-T product globally. [Read more…]